Tarsus Pharmaceuticals Trend 2026

Tarsus Pharmaceuticals develops targeted therapies for chronic eye and skin conditions. Its lead treatment, Xdemvy, targets Demodex mites responsible for blepharitis and rosacea. Patients suffering from persistent eyelid inflammation or facial redness benefit most, as the medication directly addresses the underlying parasitic cause, offering relief where traditional treatments often fail.